Maravai LifeSciences Holdings Inc To Host R&D Day Transcript
(technical difficulty) Maravai LifeSciences Investor R&D Day. We're really happy to have you here with us in New York, and to those of you online, welcome. I would like to first introduce myself. I'm Deb Hart. I lead Investor Relations for Maravai. I think I've met most of you.
I also want to point you to our disclaimers. We will be making forward-looking statements today, so please refer to our risk factors in our SEC filings. We also might refer to EBITDA figures. So we have reconciliations to any historic EBITDA on our press releases.
We have an outstanding lineup for you today. Starting off with Trey Martin, who's our newly appointed CEO as of about 9 weeks ago. He's going to introduce the company. He's followed by Dr. Kate Broderick, who leads our innovation team, Chief Innovation Officer, and she'll talk about our customer-focused innovation road map. After Kate, we have leaders of our Nucleic Acid Production team. Drew Burch is our General Manager, Executive Vice President of Nucleic Acid Products. He'll
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |